CliffBio
small molecule

ACUVAIL

KETOROLAC TROMETHAMINE

Loss of exclusivityAugust 2029latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameACUVAIL
Active ingredientKETOROLAC TROMETHAMINE
Strength0.45%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusRX

Listed patents

PatentExpiresType
7842714August 2029substance, product
8512717March 2028product
9192571March 2028product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.